In this study, 24/213 (11%) glioma patients with presumed tumor predisposition carried GVs in CPGs that potentially sensitize them to targeted therapies not routinely used in glioma patients, such as PARP, immune checkpoint, EGFR, or CDK4/6 inhibitors (Fig. 5). This evidence concerns the gene EGFR and central nervous system cancer.